skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 

Those inflationary fears rattled equities on Tuesday, with London’s AIM index underperforming the main board to reach the bell twelve and a half points lower at 1255.72, just a shade above the closing low from September 20th.

  • Pantheon Resources +20%
  • ValiRx +18%
  • NAHL -17%
  • Eden Research -13%
  • MyHealthChecked +12%

Pantheon Resources [LON:PANR] topped the board, adding 20% on a frantic day of trade for the company. Rising oil prices are cheering the stock, which now sits at levels not seen in four and a half years so this combined with speculation that the reserves the company is sitting on may be far larger than first thought makes for a compelling proposition.


ValiRx [LON:VAL] was the day’s second biggest riser by the bell. Gains of 18% have been delivered off the back of an investor presentation which appeared to bolster confidence that at least one deal will fall into place soon.

A notable mention for MyHealthChecked [LON:MHC] whose shares added 12% today. The company found its stock under pressure earlier this month as government unwinding of some travel testing took a toll. Today’s gains are marred by thin volumes and a wide spread, but tomorrow should see the release of a Q3 trading update which ought to reinforce that at least the last few months have been profitable for the business.

NAHL [LON:NAH] was the day’s biggest faller, reversing some 17% off the back of this morning’s interim results. That fall comes despite only a very modest decline in revenues and profits as a result of reduced activity as a result of COVID lockdowns. However it’s the profit downgrade for the full year – the number will be below what was achieved in 2020 – which is really damping spirits here.

Eden Research [LON:EDEN] also struggled, slipping 13% off the back of its half year report. Although the company notes a slow return towards normality, it adds that stakeholders across agriculture at all levels have been impacted and this will take some years to recover, damping demand. There is some potentially exciting news in the pipe with hopes that US regulators will approve products ahead of the 2022 growing season, but failure for this to materialise will obviously risk knocking sentiment further.

Become a better investor with SharePad Designed to give you the confidence to pick your own investments, Sharepad gives you access to a wealth of information on UK, US & European stocks. Find out more

Please note this article does not constitute investment advice. Investors are encouraged to do their own research beforehand or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we are following most closely. They all represent significant growth stories in our view. Our in-depth reports go into more detail on why we like them.

Comments


Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Pepperstone
FP Markets
IG
Spreadex
Trade Nation
WisdomTree
ActivTrades
Back To Top